Audentes Therapeutics, Inc. is a biotechnology company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
These positive earnings estimate revisions suggest that analysts are becoming more optimistic on BOLD’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Audentes Therapeutics could be a solid choice for investors.
Current Quarter Estimates for BOLD
In the past 30 days, one estimate has gone higher for Audentes Therapeutics while none have gone lower in the same time period. The trend has been pretty favorable too, with estimates narrowing from a loss of 91 cents a share 30 days ago, to a loss of 80 cents today, a move of 12.1%.
Current Year Estimates for BOLD
Meanwhile, Audentes Therapeutics’ current year figures are also looking quite promising, with one estimate moving higher in the past month, compared to one lower. The consensus estimate trend has actually seen a boost for this time frame, narrowing from a loss of $3.84 per share 30 days ago to a loss of $3.54 per share today, an increase of 7.8%.
Bottom Line
The stock has also started to move higher lately, adding 7.6% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So investors may definitely want to consider this Zacks Rank #3 (Hold) stock to profit in the near future. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Zacks' Hidden Trades
While we share many recommendations and ideas with the public, certain moves are hidden from everyone but selected members of our portfolio services. Would you like to peek behind the curtain today and view them?
Starting now, for the next month, I invite you to follow all Zacks' private buys and sells in real time from value to momentum...from stocks under $10 to ETF to option movers...from insider trades to companies that are about to report positive earnings surprises (we've called them with 80%+ accuracy). You can even look inside portfolios so exclusive that they are normally closed to new investors.
Click here for Zacks' secret trade>>
Image: Bigstock
Why Audentes Therapeutics (BOLD) Could Be Positioned for a Surge
Audentes Therapeutics, Inc. is a biotechnology company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
These positive earnings estimate revisions suggest that analysts are becoming more optimistic on BOLD’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Audentes Therapeutics could be a solid choice for investors.
Current Quarter Estimates for BOLD
In the past 30 days, one estimate has gone higher for Audentes Therapeutics while none have gone lower in the same time period. The trend has been pretty favorable too, with estimates narrowing from a loss of 91 cents a share 30 days ago, to a loss of 80 cents today, a move of 12.1%.
Current Year Estimates for BOLD
Meanwhile, Audentes Therapeutics’ current year figures are also looking quite promising, with one estimate moving higher in the past month, compared to one lower. The consensus estimate trend has actually seen a boost for this time frame, narrowing from a loss of $3.84 per share 30 days ago to a loss of $3.54 per share today, an increase of 7.8%.
Audentes Therapeutics, Inc. Price and Consensus
Audentes Therapeutics, Inc. Price and Consensus | Audentes Therapeutics, Inc. Quote
Bottom Line
The stock has also started to move higher lately, adding 7.6% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So investors may definitely want to consider this Zacks Rank #3 (Hold) stock to profit in the near future. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Zacks' Hidden Trades
While we share many recommendations and ideas with the public, certain moves are hidden from everyone but selected members of our portfolio services. Would you like to peek behind the curtain today and view them?
Starting now, for the next month, I invite you to follow all Zacks' private buys and sells in real time from value to momentum...from stocks under $10 to ETF to option movers...from insider trades to companies that are about to report positive earnings surprises (we've called them with 80%+ accuracy). You can even look inside portfolios so exclusive that they are normally closed to new investors.
Click here for Zacks' secret trade>>